Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z

CDC Media Relations
Media Home | Contact Us
US Department of Health and Human Services logo and link

Media Relations Links
About Us
Media Contact
Frequently Asked Questions
Media Site Map

CDC News
Press Release Library
MMWR Summaries
B-Roll Footage
Upcoming Events

Related Links
Centers at CDC
Data and Statistics
Health Topics A-Z
Image Library
Publications, Software and Other Products
Global Health Odyssey
Find your state or local health department
HHS News
National Health Observances
Visit the FirstGov Web Site
Div. of Media Relations
1600 Clifton Road
MS D-14
Atlanta, GA 30333
(404) 639-3286
Fax (404) 639-7394

April 18, 2002
Contact: CDC Media Relations
(404) 639-3286

Fact Sheet

New Variant CJD: Fact Sheet

New variant CJD (vCJD) is a rare, degenerative, fatal brain disorder.

Although experience with this new disease is limited, evidence to date indicates that there has never been a case transmitted person to person.

As of April 2, 2002, a total of 125 cases of vCJD had been reported in the world: 117 from the United Kingdom, six from France, and one each from Ireland and Italy.

Almost all the 125 vCJD patients had multiple-year exposures in the United Kingdom between 1980 and 1996 during the occurrence of a large UK outbreak of bovine spongiform encephalopathy (BSE, commonly known as mad cow disease) among cattle.

There has never been a case of vCJD that did not have a history of exposure within a country where this cattle disease, BSE, was occurring.

To date, despite an active USDA surveillance program, no case of this cattle disease has been identified in the United States.

It is believed that the persons who have developed vCJD became infected through their consumption of cattle products contaminated with the agent of BSE. There is no known treatment of vCJD and it is invariably fatal.

The vCJD should not be confused with the classic form of CJD that is endemic throughout the world, including the United States. The median age at death of patients with classic CJD in the United States, for example, is 68 years, and very few cases occur in persons under 30 years of age. In contrast, the median age at death of patients with vCJD in the United Kingdom is 28 years.

The vCJD can be confirmed only through examination of brain tissue obtained by biopsy or at autopsy, but a "probable case" of vCJD can be diagnosed on the basis of clinical criteria developed in the United Kingdom.

The incubation period for vCJD is unknown because it is a new disease. However, it is likely that ultimately this incubation period will be measured in terms of many years or decades. In other words, whenever a person develops vCJD from consuming a BSE-contaminated product, he or she likely would have consumed that product many years or a decade or more earlier.

In contrast to classic CJD, vCJD in the United Kingdom predominantly affects younger people, has atypical clinical features, with prominent psychiatric or sensory symptoms at the time of clinical presentation and delayed onset of neurologic abnormalities, including ataxia within weeks or months, dementia and myoclonus late in the illness, a duration of illness of at least 6 months, and a diffusely abnormal non-diagnostic electroencephalogram.

The BSE epidemic in the United Kingdom reached its peak incidence in January 1993 at almost 1,000 new cases per week. The outbreak may have resulted from the feeding of scrapie-containing sheep meat-and-bone meal to cattle. There is strong evidence and general agreement that the outbreak was amplified by feeding rendered bovine meat-and-bone meal to young calves.

The Centers for Disease Control and Prevention (CDC) monitors the trends and current incidence of CJD in the United States by analyzing death certificate information from U.S. multiple cause-of-death data, compiled by the National Center for Health Statistics, CDC. By 4-year periods from 1987 through 1998, the average annual death rates of CJD (not vCJD) have remained relatively constant, ranging from 0.98 cases per 1 million in 1987-1990 to 1.03 cases per 1 million in 1995-1998. In addition, CJD deaths in persons aged <30 years in the United States remain extremely rare (<5 cases per 1 billion per year). In contrast, in the United Kingdom, over half of the patients who died with vCJD were in this young age group.

In addition, CDC collects, reviews and when indicated, actively investigates reports by health care personnel or institutions of possible CJD or vCJD cases. Also, in 1996-97, CDC established, in collaboration with the American Association of Neuropathologists, the National Prion Disease Pathology Surveillance Center at Case Western Reserve University, which performs special diagnostic tests for prion diseases including post-mortem tests for vCJD.

Prevention measures

According to the Animal and Plant Health Inspection Service of the U.S. Department of Agriculture, BSE has not been detected in the United States, despite active surveillance efforts since May 1990. To prevent BSE from entering the United States, severe restrictions were placed on the importation of live ruminants, such as cattle, sheep and goats, and certain ruminant products from countries where BSE was known to exist. These restrictions were later extended to include importation of ruminants and certain ruminant products from all European countries.

It is extremely unlikely that BSE would be a foodborne hazard in this country. Because the use of ruminant tissue in ruminant feed was probably a necessary factor responsible for the BSE outbreak in the United Kingdom and because of the current evidence for possible transmission of BSE to humans, the U.S. Food and Drug Administration instituted a ruminant feed ban in June 1997 that became fully effective as of October 1997.

In late 2001, the Harvard Center for Risk Assessment concluded in its study of various scenarios involving BSE in the U.S., that the FDA ruminant feed rule provides a major defense against this disease.

BSE/TSE Action Plan of the Department of Health and Human Services (DHHS)

The BSE/TSE Action Plan of DHHS has four major components:

  • Surveillance for human disease is primarily the responsibility of CDC.

  • Protection is primarily the responsibility of the Food and Drug Administration (FDA).

  • Research is primarily the responsibility of the National Institutes of Health (NIH).

  • Oversight is primarily the responsibility of the Office of the Secretary of DHHS.


The Centers for Disease Control and Prevention (CDC protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

Media Home Page | Accessibility | Privacy Policy | Contact Us

CDC Home | Search | Health Topics A-Z

This page last updated April 18, 2002

United States Department of Health and Human Services
Centers for Disease Control and Prevention
Office of Communication
Division of Media Relations